-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Following Recent Decline, Sino Biopharmaceutical Limited's (HKG:1177) Top Shareholder CEO Eric S. Y. Tse Sees Holdings Value Drop by 5.8%
Following Recent Decline, Sino Biopharmaceutical Limited's (HKG:1177) Top Shareholder CEO Eric S. Y. Tse Sees Holdings Value Drop by 5.8%
If you want to know who really controls Sino Biopharmaceutical Limited (HKG:1177), then you'll have to look at the makeup of its share registry. We can see that individual insiders own the lion's share in the company with 36% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
And last week, insiders endured the biggest losses as the stock fell by 5.8%.
Let's take a closer look to see what the different types of shareholders can tell us about Sino Biopharmaceutical.
Check out our latest analysis for Sino Biopharmaceutical
SEHK:1177 Ownership Breakdown August 25th 2022What Does The Institutional Ownership Tell Us About Sino Biopharmaceutical?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
We can see that Sino Biopharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Sino Biopharmaceutical, (below). Of course, keep in mind that there are other factors to consider, too.
SEHK:1177 Earnings and Revenue Growth August 25th 2022We note that hedge funds don't have a meaningful investment in Sino Biopharmaceutical. The company's CEO Eric S. Y. Tse is the largest shareholder with 22% of shares outstanding. France Investment (China 1) Group Limited is the second largest shareholder owning 12% of common stock, and Ping Tse holds about 8.7% of the company stock. Interestingly, the third-largest shareholder, Ping Tse is also a Vice Chairman, again, indicating strong insider ownership amongst the company's top shareholders.
To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
Insider Ownership Of Sino Biopharmaceutical
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems insiders own a significant proportion of Sino Biopharmaceutical Limited. Insiders own HK$27b worth of shares in the HK$75b company. That's quite meaningful. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
General Public Ownership
With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Sino Biopharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
It seems that Private Companies own 12%, of the Sino Biopharmaceutical stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Sino Biopharmaceutical better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Sino Biopharmaceutical .
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道誰真正控制了中國生物製藥股份有限公司(HKG:1177),那麼你就得看看它的股份登記處的構成。我們可以看到,個人內部人士擁有公司的最大份額,擁有36%的股份。換句話説,該集團將從他們對公司的投資中獲得最大(或損失最大)。
上週,內部人士遭受了最大的損失,該股下跌5.8%。
讓我們仔細看看不同類型的股東能告訴我們關於中國生物製藥的什麼。
看看我們對中國生物製藥的最新分析
聯交所:1177擁有權分類2022年8月25日關於中國生物製藥,機構所有制告訴了我們什麼?
許多機構以一個接近當地市場的指數來衡量它們的表現。因此,他們通常更關注那些被納入主要指數的公司。
我們可以看到,中國生物製藥確實有機構投資者,他們持有公司很大一部分股票。這表明在專業投資者中有一定的可信度。但我們不能僅僅依靠這一事實,因為機構有時會做出糟糕的投資,就像每個人一樣。如果兩個大型機構投資者試圖同時拋售一隻股票,股價大幅下跌的情況並不少見。因此,值得查看中國生物製藥過去的收入軌跡(見下圖)。當然,請記住,還有其他因素需要考慮。
聯交所:1177盈利及收入增長2022年8月25日我們注意到,對衝基金並沒有對中國生物製藥進行有意義的投資。該公司首席執行長謝霆鋒(Eric S.Y.Tse)是最大股東,持有22%的流通股。法國投資(中國一)集團有限公司是第二大股東,持有12%的普通股,平澤持有公司約8.7%的股份。有趣的是,第三大股東謝平也是副董事長,這再次表明公司的大股東擁有強大的內部人所有權。
為了讓我們的研究更有趣,我們發現,前5名股東控制着公司一半以上的股份,這意味着這一羣體對公司的決策具有相當大的影響力。
雖然研究一家公司的機構持股可以增加你的研究價值,但研究分析師的建議以更深入地瞭解一隻股票的預期表現也是一個很好的做法。有相當數量的分析師追蹤該股,因此瞭解他們對未來的總體看法可能是有用的。
中國生物製藥的內部人所有權
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同。我們的數據反映了個別內部人士,至少捕捉到了董事會成員。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
內部人士似乎持有中國生物製藥股份有限公司相當大的比例。內部人士持有這家市值750億港元的公司價值270億港元的股票。這是很有意義的。很高興看到這樣的投資水平。你可以在這裏查看這些內部人士最近是否一直在買入。
一般公有制
擁有33%股權的普通公眾,主要由個人投資者組成,對中國生物製藥有一定程度的影響力。雖然這羣人不一定能發號施令,但它肯定能對公司的運營方式產生真正的影響。
私營公司所有權
看起來,民營企業持有中國生物製藥12%的股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
接下來的步驟:
擁有一家公司股票的不同集團總是值得考慮的。但要更好地理解中國生物製藥,我們還需要考慮許多其他因素。為此,您應該意識到1個警告標誌我們已經看到了中國生物製藥。
但最終這就是未來,而不是過去,這將決定這家企業的所有者將做得多好。因此,我們認為,看看這份免費報告是明智的,它顯示了分析師是否預測到了更光明的未來。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧